429 related articles for article (PubMed ID: 24835673)
1. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.
Ihaddadene R; Le Gal G; Delluc A; Carrier M
Thromb Res; 2014 Jul; 134(1):93-5. PubMed ID: 24835673
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
Carrier M; Le Gal G; Cho R; Tierney S; Rodger M; Lee AY
J Thromb Haemost; 2009 May; 7(5):760-5. PubMed ID: 19245418
[TBL] [Abstract][Full Text] [Related]
3. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
6. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
[TBL] [Abstract][Full Text] [Related]
7. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
[TBL] [Abstract][Full Text] [Related]
9. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.
Napolitano M; Saccullo G; Malato A; Sprini D; Ageno W; Imberti D; Mascheroni D; Bucherini E; Gallucci P; D'Alessio A; Prantera T; Spadaro P; Rotondo S; Di Micco P; Oriana V; Urbano O; Recchia F; Ghirarduzzi A; Lo Coco L; Mancuso S; Casuccio A; Rini GB; Siragusa S
J Clin Oncol; 2014 Nov; 32(32):3607-12. PubMed ID: 25267738
[TBL] [Abstract][Full Text] [Related]
10. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
[TBL] [Abstract][Full Text] [Related]
11. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
12. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
13. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study.
Kopolovic I; Lee AY; Wu C
Ann Hematol; 2015 Feb; 94(2):329-36. PubMed ID: 25190031
[TBL] [Abstract][Full Text] [Related]
14. LMWH in cancer patients with renal impairment - better than warfarin?
Bauersachs RM
Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
[TBL] [Abstract][Full Text] [Related]
15. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
[TBL] [Abstract][Full Text] [Related]
16. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study.
Vitale FV; Rotondo S; Sessa E; Parisi A; Giaimo V; D'Angelo A; Antonelli G; Romeo P; Ferraù F
J Oncol Pharm Pract; 2012 Mar; 18(1):10-6. PubMed ID: 21228085
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of venous thrombosis in cancer patients: practical aspects].
Laza-Achille M; Desruennes E; Di Palma M
Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
[TBL] [Abstract][Full Text] [Related]
19. A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism.
Kleinjan A; Aggarwal A; Van de Geer A; Faselis C; Büller HR; Di Nisio M; Rickles FR; Kamphuisen PW
Thromb Haemost; 2013 Nov; 110(5):959-65. PubMed ID: 23945725
[TBL] [Abstract][Full Text] [Related]
20. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
